Determination of midazolam in human plasma by solid-phase microextraction and gas chromatography/mass spectrometry.
A new method is described for the qualitative and quantitative analysis of midazolam, a short-acting 1,4-imidazole benzodiazepine, in human plasma. It involves a plasma deproteinization step, solid-phase microextraction (SPME) of midazolam using an 85-microm polyacrylate fiber, and its detection by gas chromatography/mass spectrometry (GC/MS) in selected ion monitoring (SIM) mode, using pinazepam as internal standard. The assay is linear over a midazolam plasma range of 1.5-300 ng/mL, relative intra- and inter-assay standard deviations at 5 ng/mL are below 7%, and the limit of detection is 1 ng/mL. The method is simple, fast and sufficiently sensitive to be applied in clinical and forensic toxicology as well as for purposes of therapeutic drug monitoring.
Frison
G
G
Forensic Toxicology and Antidoping, University Hospital of Padova, Via Falloppio 50, I-35121 Padova, Italy.
Tedeschi
L
L
Maietti
S
S
Ferrara
S D
SD
D014151:Anti-Anxiety Agents / Q000097:blood*; D002138:Calibration; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D006993:Hypnotics and Sedatives / Q000097:blood*; D008874:Midazolam / Q000097:blood*
D014151:Anti-Anxiety Agents; D006993:Hypnotics and Sedatives; D008874:Midazolam